Researchers from Critical Analytics for Manufacturing Personalized-Medicine (CAMP), an Interdisciplinary Research Group (IRG) at the Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, have identified a critical quality attribute (CQA) for the possible development of a rapid and sensitive process analytical technology (PAT) for sterility. Specifically, this technology enables the detection of early-stage microbial contaminations in human cell therapy products (CTPs).
Click here for original story, Early-stage detection of microbial contamination in cell therapy products
Source: Phys.org